NXT2

Across TCGA pan-cancer cohorts, NXT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NXT2 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NXT2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NXT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where NXT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.799	0.390	.004	14	view →
PDAC	OS	Median	II,III,IV	0.501	0.250	.007	8	view →
LSCC	DFS	Median	All	0.918	0.698	.003	6	view →
HNSC	DFS	Tertile	IV	0.941	0.640	.022	5	view →
CCRCC	OS	Median	All	0.897	1.000	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NXT2–LUAD (OS)

Open the LUAD breakdown →